SynthesisJournal of Korean medical science2025
Global Prevalence of Combustible Cigarettes and Noncombustible Nicotine or Tobacco Products Use Among Adolescents, 2014-2021.
Synthesis in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Narrative Review of Novel Nicotine-Delivery Systems and Emerging Pharmaceuticals for Tobacco Cessation.Medicines (Basel, Switzerland) · 2026Review
- Cigarette Smoke Extract Alters the Inflammatory Secretome of Osteoarthritis-Affected Synovium Increasing Joint Tissue Oxidative Stress in an Indirect Co-Culture Model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundUnderstanding global patterns of adolescent noncombustible nicotine or tobacco product (NNTP) and combustible cigarette (CC) use is vital due to rising prevalence and long-term health risks, but comparative international analyses are lacking. Thus, we aimed to assess smoking prevalence and trends among adolescents in 57 countries and territories and to identify factors associated with NNTP and CC use.
methodsWe utilized World Health Organization (WHO) Global Youth Tobacco Survey data to investigate adolescent NNTP and CC use prevalence and trends globally from 2014 to 2021. We conducted a meta-analysis using random-effects models to identify the summary effect of smoking prevalence in each country. Weighted linear regression was used to calculate weighted β coefficients with 95% confidence intervals (CIs). Each analysis was stratified by sex, World Bank income category, e-cigarette regulatory policy status, and WHO Framework Convention on Tobacco Control ratification status. Finally, a hierarchical Bayesian statistical model was employed to precisely predict the prevalence rates of both CC and NNTP use up to 2045.
resultsAmong the 57 countries with 173,658 adolescents, NNTP use exhibited a higher prevalence than CC use in 31 countries. Demographic groups exhibiting higher smoking prevalence included male adolescents (NNTP use: 10.78% [95% CI, 9.38 to 12.18]; CC use: 10.36% [9.03 to 11.69]), adolescents in high-income countries (NNTP use: 11.29% [8.62 to 13.95]; CC use: 10.48% [7.27 to 13.68]), and those in countries with less restrictive policies (NNTP use: 11.18% [7.32 to 15.04]; CC use: 11.44% [7.75 to 15.13]). Global NNTP use showed an overall increase from 2014 to 2021 (β, 0.73 [0.16 to 1.30]), with a particularly notable rise among male adolescents (β, 0.81 [0.05 to 1.57]). In 2044-2045, NNTP use is expected to remain relatively stable (10.61%), while CC use is projected to show a downward trend (1.05%).
conclusionOver half of the countries exhibited a higher prevalence of NNTP use than CC use. Global smoking prevalence varied across diverse factors. NNTP use among adolescents has increased, especially among male adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.